Brodalumab: First Global Approval.
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|September 1, 2016
Summary
Brodalumab is a new biologic treatment approved in Japan for psoriasis. It targets interleukin-17 receptor A to reduce inflammation, offering a novel therapeutic option for patients.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory skin condition with limited treatment options.
- Interleukin-17 (IL-17) signaling plays a key role in the pathogenesis of psoriasis.
- Brodalumab is a targeted therapy developed to address IL-17-mediated inflammation.
Purpose of the Study:
- To summarize the development of brodalumab, a novel biologic agent.
- To highlight the milestones leading to its regulatory approval for psoriasis treatment.
- To provide an overview of brodalumab's mechanism of action.
Main Methods:
- Review of preclinical and clinical development data for brodalumab.
- Analysis of brodalumab's binding affinity to interleukin-17 receptor A.
- Summary of regulatory submissions and approvals in Japan.
Main Results:
- Brodalumab, a human monoclonal antibody, effectively targets IL-17 receptor A.
- Inhibition of IL-17 receptor A modulates key pro-inflammatory cytokines.
- Brodalumab has received approval in Japan for treating various forms of psoriasis.
Conclusions:
- Brodalumab represents a significant advancement in psoriasis treatment.
- Its targeted mechanism offers a new therapeutic strategy for managing psoriatic diseases.
- Further regulatory reviews are ongoing in the USA, EU, and Canada.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
697
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
697
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
639
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639
01:26FDA Approved Drugs: Changes to Approved Drugs
313
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
313
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
596
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
596
01:28Drug Products: Biologics, Biosimilars and Interchangeables
342
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
342
01:29Drugs for Treatment of Ulcerative Colitis in IBD
592
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
592